BRPI1008230A2 - " peptídeo de penetração celular e composições farmacêuticas " - Google Patents
" peptídeo de penetração celular e composições farmacêuticas "Info
- Publication number
- BRPI1008230A2 BRPI1008230A2 BRPI1008230A BRPI1008230A BRPI1008230A2 BR PI1008230 A2 BRPI1008230 A2 BR PI1008230A2 BR PI1008230 A BRPI1008230 A BR PI1008230A BR PI1008230 A BRPI1008230 A BR PI1008230A BR PI1008230 A2 BRPI1008230 A2 BR PI1008230A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- cell penetration
- penetration peptide
- peptide
- cell
- Prior art date
Links
- 230000035515 penetration Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009122096 | 2009-05-20 | ||
| JPJP2009-122096 | 2009-05-20 | ||
| JPJP2010-071774 | 2010-03-26 | ||
| JP2010071774 | 2010-03-26 | ||
| PCT/JP2010/058420 WO2010134537A1 (ja) | 2009-05-20 | 2010-05-19 | 細胞膜透過性ペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1008230A2 true BRPI1008230A2 (pt) | 2016-03-08 |
| BRPI1008230B1 BRPI1008230B1 (pt) | 2019-05-28 |
Family
ID=43126214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008230-1A BRPI1008230B1 (pt) | 2009-05-20 | 2010-05-19 | Peptídeo de penetração celular e composição farmacêutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8772449B2 (pt) |
| EP (1) | EP2433953B1 (pt) |
| JP (1) | JP5653214B2 (pt) |
| KR (1) | KR101783291B1 (pt) |
| CN (1) | CN102428096B (pt) |
| AU (1) | AU2010250452B2 (pt) |
| BR (1) | BRPI1008230B1 (pt) |
| CA (1) | CA2762551C (pt) |
| ES (1) | ES2546304T3 (pt) |
| MX (1) | MX2011011960A (pt) |
| PL (1) | PL2433953T3 (pt) |
| RU (1) | RU2548807C2 (pt) |
| WO (1) | WO2010134537A1 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102580061B (zh) * | 2011-12-01 | 2015-04-22 | 武汉健宇生物医药科技有限公司 | 一种鼻用型胰岛素制剂及制备方法 |
| WO2013167299A1 (en) | 2012-05-11 | 2013-11-14 | Kael-Gemvax Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
| US9730984B2 (en) | 2012-05-11 | 2017-08-15 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating rheumatoid arthritis |
| WO2014010971A1 (ko) * | 2012-07-11 | 2014-01-16 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| CN104768967B (zh) | 2012-09-19 | 2019-02-15 | 珍白斯凯尔有限公司 | 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 |
| US9572900B2 (en) | 2012-09-19 | 2017-02-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| JP6474786B2 (ja) | 2013-04-19 | 2019-02-27 | ジェムバックス アンド カエル カンパニー，リミティド | 虚血性損傷の治療及び予防用の組成物 |
| US10383926B2 (en) | 2013-06-07 | 2019-08-20 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
| ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
| CN103555729B (zh) * | 2013-10-14 | 2016-08-24 | 成都华创生物技术有限公司 | 一种改造的trail基因序列、表达方法及应用 |
| KR101691479B1 (ko) | 2013-10-23 | 2017-01-02 | 주식회사 젬백스앤카엘 | 전립선 비대증 치료 및 예방용 조성물 |
| ES2818921T3 (es) | 2013-11-22 | 2021-04-14 | Gemvax & Kael Co Ltd | Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo |
| JP6367950B2 (ja) | 2013-12-17 | 2018-08-01 | ジェムバックス アンド カエル カンパニー，リミティド | 前立腺癌治療用組成物 |
| ES2908096T3 (es) | 2014-04-11 | 2022-04-27 | Gemvax & Kael Co Ltd | Péptido con actividad inhibidora de la fibrosis y composición que lo contiene |
| CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| JP6886404B2 (ja) | 2015-01-30 | 2021-06-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 初代造血細胞におけるタンパク質送達 |
| WO2016137162A1 (ko) | 2015-02-27 | 2016-09-01 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| KR101846306B1 (ko) | 2015-03-31 | 2018-05-18 | 일동제약(주) | 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물 |
| EP3305802B1 (en) | 2015-05-26 | 2021-05-12 | Gemvax & Kael Co., Ltd. | Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same |
| KR101647804B1 (ko) * | 2015-06-24 | 2016-08-11 | 한국과학기술연구원 | 신규 세포투과 펩타이드 및 이의 용도 |
| ES2886946T3 (es) | 2015-07-02 | 2021-12-21 | Gemvax & Kael Co Ltd | Péptido con efecto antiviral y composición que lo contiene |
| CN108135962A (zh) | 2015-10-07 | 2018-06-08 | 塞浦路迈德有限责任公司 | 用于口服递送肽类药物的药物制剂 |
| WO2017127567A1 (en) * | 2016-01-19 | 2017-07-27 | Genebiologics, Llc | Production of arginine-rich proteins and use as a fertilizer and germination enhancer |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| CA3045599A1 (en) * | 2016-12-16 | 2018-06-21 | Avixgen Inc | Cytoplasmic transduction peptide and intracellular messenger comprising same |
| JP2019099578A (ja) * | 2017-12-06 | 2019-06-24 | 参天製薬株式会社 | 細胞膜透過性ペプチドを含有する眼科用医薬組成物 |
| KR101933217B1 (ko) | 2017-12-28 | 2018-12-27 | (주) 에빅스젠 | 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물 |
| MX2020010323A (es) | 2018-04-03 | 2021-01-08 | Ngm Biopharmaceuticals Inc | Agentes de union al componente del complemento c3 (c3) y metodos para su uso. |
| JP7442823B2 (ja) | 2018-04-06 | 2024-03-05 | シプルメット・ゲーエムベーハー | 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CN109553659B (zh) * | 2018-11-26 | 2022-06-21 | 上海华新生物高技术有限公司 | 一种细胞穿透肽及透皮干扰素 |
| CN109575107B (zh) * | 2018-11-26 | 2022-03-08 | 上海华新生物高技术有限公司 | 一种细胞穿透肽及可表达口服干扰素的双歧杆菌 |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| EP4210680A1 (en) | 2020-09-07 | 2023-07-19 | Cyprumed GmbH | Improved pharmaceutical formulations of glp-1 receptor agonists |
| CN116507364A (zh) | 2020-10-16 | 2023-07-28 | 学校法人常翔学园 | 组合物 |
| CN114805593A (zh) * | 2021-01-19 | 2022-07-29 | 盛世泰研(广东)健康科技有限公司 | 一种具有穿膜功能的Penetratin-hSOD1及其制备方法与应用 |
| KR20220157778A (ko) * | 2021-05-21 | 2022-11-29 | 원큐어젠 주식회사 | 세포 투과성 펩타이드 및 글루카곤 유사 펩타이드-1 수용체 작용제를 포함하는 복합체 |
| WO2023166179A1 (en) | 2022-03-03 | 2023-09-07 | Cyprumed Gmbh | Improved oral pharmaceutical formulations of therapeutic peptides and proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2702285B2 (ja) | 1992-08-21 | 1998-01-21 | バイオジェン，インコーポレイテッド | Ｔａｔ由来の輸送ポリペプチド |
| JP3770666B2 (ja) | 1996-09-20 | 2006-04-26 | 株式会社ティ・ティ・エス技術研究所 | 経粘膜吸収製剤用組成物 |
| WO2000029427A2 (en) * | 1998-11-13 | 2000-05-25 | Cyclacel Limited | Antennapedia homeodomain helix 3 derived translocation vectors |
| CA2502118A1 (en) | 2002-10-11 | 2004-05-06 | Sanwa Kagaku Kenkyusho Co., Ltd. | Glp-1 derivatives and transmicosal absorption preparations thereof |
| US7385027B2 (en) * | 2003-01-07 | 2008-06-10 | University Of Kentucky Research Foundation | Membrane-permeable peptide capable of calpain inhibition |
| JP2005185271A (ja) * | 2003-12-03 | 2005-07-14 | Credia Japan:Kk | 膜透過性ペプチド核酸 |
| EP1814913B1 (en) * | 2004-11-05 | 2015-08-19 | IGM Biosciences, Inc. | Antibody induced cell membrane wounding |
| ES2671024T3 (es) * | 2008-02-28 | 2018-06-04 | Toray Industries, Inc. | Composición farmacéutica para administración transnasal |
| CN102580061B (zh) * | 2011-12-01 | 2015-04-22 | 武汉健宇生物医药科技有限公司 | 一种鼻用型胰岛素制剂及制备方法 |
-
2010
- 2010-05-19 CA CA2762551A patent/CA2762551C/en active Active
- 2010-05-19 CN CN201080021804.XA patent/CN102428096B/zh active Active
- 2010-05-19 MX MX2011011960A patent/MX2011011960A/es active IP Right Grant
- 2010-05-19 WO PCT/JP2010/058420 patent/WO2010134537A1/ja active Application Filing
- 2010-05-19 EP EP10777770.8A patent/EP2433953B1/en active Active
- 2010-05-19 RU RU2011151877/10A patent/RU2548807C2/ru active
- 2010-05-19 US US13/321,176 patent/US8772449B2/en active Active
- 2010-05-19 AU AU2010250452A patent/AU2010250452B2/en not_active Ceased
- 2010-05-19 PL PL10777770T patent/PL2433953T3/pl unknown
- 2010-05-19 ES ES10777770.8T patent/ES2546304T3/es active Active
- 2010-05-19 BR BRPI1008230-1A patent/BRPI1008230B1/pt not_active IP Right Cessation
- 2010-05-19 JP JP2010520082A patent/JP5653214B2/ja active Active
- 2010-05-19 KR KR1020117027839A patent/KR101783291B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20120065124A1 (en) | 2012-03-15 |
| BRPI1008230B1 (pt) | 2019-05-28 |
| RU2548807C2 (ru) | 2015-04-20 |
| MX2011011960A (es) | 2011-12-06 |
| KR101783291B1 (ko) | 2017-09-29 |
| JP5653214B2 (ja) | 2015-01-14 |
| ES2546304T3 (es) | 2015-09-22 |
| JPWO2010134537A1 (ja) | 2012-11-12 |
| WO2010134537A1 (ja) | 2010-11-25 |
| EP2433953A1 (en) | 2012-03-28 |
| CA2762551C (en) | 2016-11-22 |
| US8772449B2 (en) | 2014-07-08 |
| CN102428096A (zh) | 2012-04-25 |
| EP2433953A4 (en) | 2013-06-05 |
| KR20120064650A (ko) | 2012-06-19 |
| CN102428096B (zh) | 2015-03-25 |
| RU2011151877A (ru) | 2013-06-27 |
| PL2433953T3 (pl) | 2015-12-31 |
| EP2433953B1 (en) | 2015-07-08 |
| CA2762551A1 (en) | 2010-11-25 |
| AU2010250452B2 (en) | 2014-06-05 |
| AU2010250452A1 (en) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008230A2 (pt) | " peptídeo de penetração celular e composições farmacêuticas " | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| BRPI1010761A2 (pt) | "composições semi-sólidas e produtos farmacêuticos" | |
| BRPI0906722A2 (pt) | Métodos e composições usando polipeptídeos de fusão klotho-fgf | |
| DK3178835T3 (da) | Forlængede rekombinante polypeptider og sammensætninger omfattende samme | |
| BRPI0924137A2 (pt) | composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade | |
| BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
| BRPI0810928A2 (pt) | "composição farmacêutica" | |
| BRPI0918652A2 (pt) | Composições farmacêuticas e métodos de libração relacionadas. | |
| DK2504353T4 (da) | Lipopeptidsammensætninger og tilsvarende fremgangsmåder | |
| BRPI1012787A2 (pt) | "polipeptídeos de amilase" | |
| BR112012004448A2 (pt) | "compostos e composições como inibidores de proteína cinase" | |
| BRPI0822221A2 (pt) | Composições aquosas e estáveis de ciclosporina | |
| BRPI0911743A2 (pt) | "peptídeo" | |
| BRPI0905715A2 (pt) | Composição farmacêutica e kit de componentes | |
| BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
| DK3834841T3 (da) | Stabiliserede væskeformige og lyofiliserede adamts13-formuleringer | |
| SI2154966T1 (sl) | Benzimidazoli in njihovi farmacevtski sestavki | |
| BRPI0908132A2 (pt) | Composto de benzodiazepina e composição farmacêutica | |
| BRPI1007194A2 (pt) | Composição compreendendo ácido chicórico e/ou derivados do mesmo | |
| BRPI1006666A2 (pt) | " composição farmacêutica e uso de uma composição farmacêutica" | |
| DK2114452T3 (da) | Forbedrede medicinsammensætninger omfattende buprenorfin og nalmefen | |
| BRPI1008147A2 (pt) | composição de xampu concentrado e xampu centrado | |
| BRPI0912074A2 (pt) | composto e composição farmacêutica | |
| DK2271321T3 (da) | Farmaceutisk sammensætning 271 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2010, OBSERVADAS AS CONDICOES LEGAIS |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |